Bausch Health Secures Alberta Reimbursement for SILIQ, Expanding Psoriasis Treatment Access
Event summary
- Bausch Health's SILIQ (brodalumab injection) now covered under Alberta's public drug plan for eligible patients with moderate to severe plaque psoriasis.
- Alberta is the second-to-last Canadian province to add SILIQ to its public drug plan, with only British Columbia remaining.
- SILIQ has been available in Canada since 2018 and is indicated for systemic therapy or phototherapy candidates.
- The drug works by blocking IL-17 proteins, which are elevated in psoriasis patients.
The big picture
This reimbursement decision is a strategic win for Bausch Health, bringing SILIQ closer to nationwide public coverage in Canada. The move aligns with broader industry trends toward expanding access to biologic therapies for chronic dermatologic conditions. With psoriasis affecting 1-3% of Canadians, this approval could significantly increase patient reach and reinforce Bausch Health's position in the dermatology market.
What we're watching
- Market Penetration
- Whether Bausch Health can secure reimbursement in British Columbia, achieving full national coverage.
- Competitive Dynamics
- How this expansion affects positioning against other psoriasis treatments in Canada.
- Patient Outcomes
- The impact of broader SILIQ access on treatment adherence and quality of life for psoriasis patients.
Related topics